Paper78050
Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
Moncada S and 1 other. Lancet, 1978. Cited by 427 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Papers, record 78050. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/78050
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dipyridamole | Major topic |
| Epoprostenol | Major topic |
| Fibrinolytic Agents | Major topic |
| Phosphodiesterase Inhibitors | Major topic |
| Platelet Aggregation | Major topic |
| Prostaglandins | Major topic |
| Thrombosis | Major topic |
| Animals | |
| Aspirin | |
| Blood Platelets | |
| Cyclooxygenase Inhibitors | |
| Depression, Chemical | |
| Dose-Response Relationship, Drug | |
| Drug Synergism | |
| Prostaglandin Antagonists | |
| Prostaglandins, Synthetic | |
| Rabbits | |
| Theophylline |
Source PubMed
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 427 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33,001,004 | Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients. | Curr Pharm Des | 2021 | https://conductscience.org/library/papers/33001004 | PubMed |
| 23,024,160 | Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? | Clin J Am Soc Nephrol | 2013 | https://conductscience.org/library/papers/23024160 | PubMed |
| 16,103,157 | Dipyridamole reversibly inhibits mengovirus RNA replication. | J Virol | 2005 | https://conductscience.org/library/papers/16103157 | PubMed |
| 15,733,010 | Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. | Drugs | 2005 | https://conductscience.org/library/papers/15733010 | PubMed |
| 12,885,264 | Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke. | Clin Pharmacokinet | 2003 | https://conductscience.org/library/papers/12885264 | PubMed |
| 10,768,906 | Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial. | Heart | 2000 | https://conductscience.org/library/papers/10768906 | PubMed |
| 9,849,048 | [Effect of intracoronary dipyridamole administration on the incidence of restenosis after PTCA. A prospective randomized study]. | Med Klin (Munich) | 1998 | https://conductscience.org/library/papers/9849048 | PubMed |
| 9,578,178 | Do we still need dipyridamole? | Br J Clin Pharmacol | 1998 | https://conductscience.org/library/papers/9578178 | PubMed |
| 8,970,869 | Short-term effect of dipyridamole on blood flow velocities in the extraocular vessels. | Int Ophthalmol | 1995 | https://conductscience.org/library/papers/8970869 | PubMed |
| 7,957,770 | Effect of dipyridamole on glomerular mesangial cell ecto-5'-nucleotidase expression. | Experientia | 1994 | https://conductscience.org/library/papers/7957770 | PubMed |
| 7,641,602 | Novel antithrombotic drugs in development. | Drugs | 1995 | https://conductscience.org/library/papers/7641602 | PubMed |
| 7,400,307 | Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery. | J Clin Invest | 1980 | https://conductscience.org/library/papers/7400307 | PubMed |
| 7,269,560 | Thrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention. | West J Med | 1981 | https://conductscience.org/library/papers/7269560 | PubMed |
| 7,262,095 | The haemolytic uraemic syndrome in childhood: a study of the long-term prognosis. | Eur J Pediatr | 1981 | https://conductscience.org/library/papers/7262095 | PubMed |
| 7,151,846 | Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time. | Eur J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/7151846 | PubMed |
| 7,077,562 | Transient cerebral ischaemic attacks. | J R Coll Physicians Lond | 1982 | https://conductscience.org/library/papers/7077562 | PubMed |
| 7,059,243 | Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter vascular prostheses (PTFE) in nonhuman primates. | Ann Surg | 1982 | https://conductscience.org/library/papers/7059243 | PubMed |
| 7,049,287 | Effect of dipyridamole on the formation of 6-oxo-prostaglandin F1 alpha by the rat isolated aorta and ram seminal vesicle microsomes. | Br J Pharmacol | 1982 | https://conductscience.org/library/papers/7049287 | PubMed |
| 7,044,460 | Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. | Br J Pharmacol | 1982 | https://conductscience.org/library/papers/7044460 | PubMed |
| 7,037,426 | Enhanced prostacyclin production by dipyridamole in man. | Eur J Clin Pharmacol | 1981 | https://conductscience.org/library/papers/7037426 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/78050
GET https://conductscience.org/api/papers/v1/78050/cited_by?page=2